Compare BTOC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | ACET |
|---|---|---|
| Founded | 2020 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 93.5M |
| IPO Year | 2024 | N/A |
| Metric | BTOC | ACET |
|---|---|---|
| Price | $0.63 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $197,399,541.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.35 | N/A |
| 52 Week Low | $0.41 | $0.45 |
| 52 Week High | $6.10 | $1.12 |
| Indicator | BTOC | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 33.71 |
| Support Level | $0.56 | $0.53 |
| Resistance Level | $0.62 | $0.57 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 86.29 | 5.35 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.